[{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Numab Therapeutics"},{"orgOrder":0,"company":"Molecular Partners","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$580.0 million","upfrontCash":"$20.0 million","newsHeadline":"Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Molecular Partners"},{"orgOrder":0,"company":"Engimmune Therapeutics","sponsor":"Pureos Bioventures","pharmaFlowCategory":"D","amount":"$16.7 million","upfrontCash":"Undisclosed","newsHeadline":"Engimmune Therapeutics Raises CHF 15.5 Million in Seed Financing to Develop Novel T-cell Receptor Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Engimmune Therapeutics"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Nodus Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nodus Oncology Announces Acquisition of Basilea Pharmaceutica\u2019s PARG Inhibitor Programme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Basilea Pharmaceutica"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Nodus Oncology","pharmaFlowCategory":"D","amount":"$251.0 million","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Sale of Preclinical Oncology Program to Nodus Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Basilea Pharmaceutica"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Whitelab Genomics","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Debiopharm"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"4BIO Capital","pharmaFlowCategory":"D","amount":"$24.0 million","upfrontCash":"Undisclosed","newsHeadline":"Araris Biotech Closes $24 Million Financing Round","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Araris Biotech"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Memo Therapeutics"},{"orgOrder":0,"company":"Opna Bio","sponsor":"Longitude Capital","pharmaFlowCategory":"D","amount":"$38.0 million","upfrontCash":"Undisclosed","newsHeadline":"Opna Bio Launches with $38 Million Series A Financing to Advance Novel Oncology Discovery Program and Diversified Pipeline of Clinical and Preclinical Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Opna Bio"},{"orgOrder":0,"company":"Elthera","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LegoChemBio Signs License Agreement to Acquire First-in-class Antibody From Elthera","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Elthera"},{"orgOrder":0,"company":"leadXpro","sponsor":"Cumulus Oncology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules Against Novel Cancer-Focused GPCR Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"leadXpro"},{"orgOrder":0,"company":"Athebio","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Athebio"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The collaboration aims to develop and commercialize DARPin in the radioligand therapy field. The parties will collaborate in discovery, candidate selection and preclinical development of Athebody® DARPins for use as Radio-DARPin drug entities.
Under the collaboration, the companies will focus on the discovery and development of small molecules targeting an undisclosed and novel cancer-focused G protein-coupled receptor (GPCR).
Under the terms of the licensing agreement, LegoChem Biosciences will develop and commercialize a novel antibody-drug conjugate (ADC) therapy using a monoclonal antibody developed by Elthera.
The proceeds will be used to develop novel fragile-X mental retardation protein (FMRP) inhibitors in oncology as well as a diverse portfolio of clinical and preclinical oncology programs acquired from Plexxikon Inc.
Under the terms of the agreement, MTx will leverage its best-in-class microfluidic single-cell molecular cloning and screening technologies to discover antibodies for immuno-oncology targets.
Proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer towards clinical development.
Debiopharm Innovation Fund strategically invests in Whitelab Genomics’ mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future.
Nodus secures worldwide development and commercialization rights to Basilea’s PARG inhibitor (PARGi) programme – currently at the discovery stage - which has the potential to be a best-in-class treatment for molecularly defined patient sub-groups.
Under the terms of the agreement, Basilea entered into an asset purchase agreement with Nodus Oncology for Basilea’s novel poly (ADP-ribose) glycohydrolase (PARG) inhibitor discovery program.
Proceeds from the financing will be used to further build Engimmune’s pipeline having T-cell receptor based therapies, expand the research team in Switzerland, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.